Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Reduced folate carrier and folylpolyglutamate synthetase, but not thymidylate synthase predict survival in pemetrexed-treated patients suffering from malignant pleural mesothelioma.

Mairinger F, Vollbrecht C, Halbwedl I, Hatz M, Stacher E, Gülly C, Quehenberger F, Stephan-Falkenau S, Kollmeier J, Roth A, Mairinger T, Popper H.

J Thorac Oncol. 2013 May;8(5):644-53. doi: 10.1097/JTO.0b013e318287c224.

2.

Thymidylate synthase and folyl-polyglutamate synthase are not clinically useful markers of response to pemetrexed in patients with malignant pleural mesothelioma.

Lustgarten DE, Deshpande C, Aggarwal C, Wang LC, Saloura V, Vachani A, Wang LP, Litzky L, Feldman M, Creaney J, Nowak AK, Langer C, Inghilleri S, Stella G, Albelda SM.

J Thorac Oncol. 2013 Apr;8(4):469-77. doi: 10.1097/JTO.0b013e318283da3e.

3.

Folylpoly-glutamate synthetase expression is associated with tumor response and outcome from pemetrexed-based chemotherapy in malignant pleural mesothelioma.

Christoph DC, Asuncion BR, Mascaux C, Tran C, Lu X, Wynes MW, Gauler TC, Wohlschlaeger J, Theegarten D, Neumann V, Hepp R, Welter S, Stamatis G, Tannapfel A, Schuler M, Eberhardt WE, Hirsch FR.

J Thorac Oncol. 2012 Sep;7(9):1440-8.

4.

TS, DHFR and GARFT expression in non-squamous cell carcinoma of NSCLC and malignant pleural mesothelioma patients treated with pemetrexed.

Uramoto H, Onitsuka T, Shimokawa H, Hanagiri T.

Anticancer Res. 2010 Oct;30(10):4309-15.

PMID:
21036757
5.

Biomarker analysis in a phase III study of pemetrexed-carboplatin versus etoposide-carboplatin in chemonaive patients with extensive-stage small-cell lung cancer.

Smit EF, Socinski MA, Mullaney BP, Myrand SP, Scagliotti GV, Lorigan P, Reck M, Ciuleanu T, von Pawel J, Karaseva NA, Szczesna A, Ohannesian D, Powell E, Hozak RR, Hong S, Guba SC, Thatcher N.

Ann Oncol. 2012 Jul;23(7):1723-9. doi: 10.1093/annonc/mdr563. Epub 2011 Dec 19.

6.
7.

In vitro chemosensitivity of freshly explanted tumor cells to pemetrexed is correlated with target gene expression.

Hanauske AR, Eismann U, Oberschmidt O, Pospisil H, Hoffmann S, Hanauske-Abel H, Ma D, Chen V, Paoletti P, Niyikiza C.

Invest New Drugs. 2007 Oct;25(5):417-23. Epub 2007 May 30.

PMID:
17534577
8.

Schedule-dependent synergistic effect of pemetrexed combined with gemcitabine against malignant pleural mesothelioma and non-small cell lung cancer cell lines.

Nagai S, Takenaka K, Sonobe M, Wada H, Tanaka F.

Chemotherapy. 2008;54(3):166-75. doi: 10.1159/000140360. Epub 2008 Jun 18.

PMID:
18560222
9.

Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin.

Zucali PA, Giovannetti E, Destro A, Mencoboni M, Ceresoli GL, Gianoncelli L, Lorenzi E, De Vincenzo F, Simonelli M, Perrino M, Bruzzone A, Thunnissen E, Tunesi G, Giordano L, Roncalli M, Peters GJ, Santoro A.

Clin Cancer Res. 2011 Apr 15;17(8):2581-90. doi: 10.1158/1078-0432.CCR-10-2873. Epub 2011 Jan 24.

10.

Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy.

Righi L, Papotti MG, Ceppi P, Billè A, Bacillo E, Molinaro L, Ruffini E, Scagliotti GV, Selvaggi G.

J Clin Oncol. 2010 Mar 20;28(9):1534-9. doi: 10.1200/JCO.2009.25.9275. Epub 2010 Feb 22.

11.

A phase II trial of pemetrexed in advanced breast cancer: clinical response and association with molecular target expression.

Gomez HL, Santillana SL, Vallejos CS, Velarde R, Sanchez J, Wang X, Bauer NL, Hockett RD, Chen VJ, Niyikiza C, Hanauske AR.

Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):832-8.

12.

Pharmacogenomic assessment of outcomes of pemetrexed-treated patients with adenocarcinoma of the lung.

Jung M, Lee CH, Park HS, Lee JH, Kang YA, Kim SK, Chang J, Kim DJ, Rha SY, Kim JH, Cho BC.

Yonsei Med J. 2013 Jul;54(4):854-64. doi: 10.3349/ymj.2013.54.4.854.

13.

The issue of studies evaluating biomarkers which predict outcome after pemetrexed-based chemotherapy in malignant pleural mesothelioma.

Mairinger F, Vollbrecht C, Mairinger T, Popper H.

J Thorac Oncol. 2013 Aug;8(8):e80-2. doi: 10.1097/JTO.0b013e31829b1cf9. No abstract available.

14.

Correlation between TS, MTHFR, and ERCC1 gene polymorphisms and the efficacy of platinum in combination with pemetrexed first-line chemotherapy in mesothelioma patients.

Powrózek T, Kowalski DM, Krawczyk P, Ramlau R, Kucharczyk T, Kalinka-Warzocha E, Knetki-Wróblewska M, Winiarczyk K, Dyszkiewicz W, Krzakowski M, Milanowski J.

Clin Lung Cancer. 2014 Nov;15(6):455-65. doi: 10.1016/j.cllc.2014.06.009. Epub 2014 Aug 15.

PMID:
25246386
15.

Induction of resistance to the multitargeted antifolate Pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression.

Sigmond J, Backus HH, Wouters D, Temmink OH, Jansen G, Peters GJ.

Biochem Pharmacol. 2003 Aug 1;66(3):431-8.

PMID:
12907242
16.

[Pemetrexed: from preclinic to clinic].

Lansiaux A, Lokiec F.

Bull Cancer. 2007;94 Spec No Actualites:S134-8. Review. French.

PMID:
17845983
17.
19.

LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes.

Shih C, Chen VJ, Gossett LS, Gates SB, MacKellar WC, Habeck LL, Shackelford KA, Mendelsohn LG, Soose DJ, Patel VF, Andis SL, Bewley JR, Rayl EA, Moroson BA, Beardsley GP, Kohler W, Ratnam M, Schultz RM.

Cancer Res. 1997 Mar 15;57(6):1116-23.

20.

[Prognosis related clinical and molecular factors in malignant pleural mesothelioma].

Wang YY, Zhang H, Bai H, Wang SH, Wu MN, An TT, Zhao J, Zhuo ML, Duan JC, Wang ZJ, Wang J.

Zhonghua Jie He He Hu Xi Za Zhi. 2013 Mar;36(3):162-8. Chinese.

PMID:
23856136
Items per page

Supplemental Content

Write to the Help Desk